US-based gene therapies company bluebird bio has entered a strategic collaboration and licence agreement with Scottish immunotherapy firm TC BioPharm to develop new cancer immunotherapy candidates.
The firms will focus on the discovery of next-generation liquid and solid tumour therapeutics based on gamma delta CAR T-cells.
Go deeper with GlobalData
In addition to TC BioPharm’s CAR-engineered gamma delta T-cell programme, the firms plan to advance various hematologic and solid tumour targets into clinical trials.
TC BioPharm chief business officer Artin Moussavi said: “We believe our gamma delta T-cell platform has broad therapeutic potential.
“The collaboration with bluebird bio, a leader in cell and gene therapy, recognises the enormous potential of ImmuniCAR to deliver life-changing medicines.”
TC BioPharm will be responsible for the development of all identified targets through Phase I/II, while bluebird exercises an exclusive option for their clinical development and commercialisation.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDatabluebird bio corporate development and strategy senior vice-president Joanne Smith-Farrell said: “bluebird bio is leveraging its industry-leading toolbox of advanced cell and gene therapy technologies to accelerate immuno-oncology targets from concept to clinic.”
According to bluebird, the deal is set to support its expanding immuno-oncology development programme of CAR T and T-Cell Receptor products that utilise the firm’s expertise on translational research and deep vector technology.
The agreement entails $16m upfront and subsequent potential research and development (R&D), as well as commercial milestone payments.
With operations in UK and Japan, TC BioPharm forms strategic alliances with pharmaceutical, biotechnology and research institutions to develop advanced cell therapies.
